ES2055469T3 - Preparado inmunoestimulante, quimicamente estable y de aplicacion parenteral; procedimiento para su produccion y su aplicacion. - Google Patents

Preparado inmunoestimulante, quimicamente estable y de aplicacion parenteral; procedimiento para su produccion y su aplicacion.

Info

Publication number
ES2055469T3
ES2055469T3 ES91102431T ES91102431T ES2055469T3 ES 2055469 T3 ES2055469 T3 ES 2055469T3 ES 91102431 T ES91102431 T ES 91102431T ES 91102431 T ES91102431 T ES 91102431T ES 2055469 T3 ES2055469 T3 ES 2055469T3
Authority
ES
Spain
Prior art keywords
application
immuno
procedure
production
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91102431T
Other languages
English (en)
Inventor
Ingrid Dr Rer Nat Wolf
Gabriele Klehr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Chemie AG
Original Assignee
Berlin Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie AG filed Critical Berlin Chemie AG
Application granted granted Critical
Publication of ES2055469T3 publication Critical patent/ES2055469T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/32—Thymopoietins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION CONSISTE EN UN PREPARADO LIOFILIZADO ESTABLE Y LIQUIDO PARA SU APLICACION COMO INMUNOESTIMULANTE EN LA MEDICINA HUMANA, EL METODO PARA SU PREPARACION, ASI COMO SU APLICACION. EL PREPARADO SE ELABORA CON UN PH ENTRE 6 Y 8 CON LA COMBINACION DE ESPLENOPENTIN O SUS ANALOGOS CON UN HIDROBENZOACIDO-ESTER Y SE CARACTERIZA POR UNA ESTABILIDAD MAYOR Y MAS DURADERA.
ES91102431T 1990-03-06 1991-02-20 Preparado inmunoestimulante, quimicamente estable y de aplicacion parenteral; procedimiento para su produccion y su aplicacion. Expired - Lifetime ES2055469T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DD90338431A DD292382B5 (de) 1990-03-06 1990-03-06 Verfahren zur herstellung eines parenteral applizierbaren lagerbestaendigen immunstimulierenden praeparats

Publications (1)

Publication Number Publication Date
ES2055469T3 true ES2055469T3 (es) 1994-08-16

Family

ID=5616877

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91102431T Expired - Lifetime ES2055469T3 (es) 1990-03-06 1991-02-20 Preparado inmunoestimulante, quimicamente estable y de aplicacion parenteral; procedimiento para su produccion y su aplicacion.

Country Status (7)

Country Link
EP (1) EP0445581B1 (es)
JP (1) JPH0692315B2 (es)
AT (1) ATE88903T1 (es)
CA (1) CA2037531A1 (es)
DD (1) DD292382B5 (es)
DE (1) DE59100098D1 (es)
ES (1) ES2055469T3 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100058559A (ko) * 2007-09-11 2010-06-03 몬도바이오테크 래보래토리즈 아게 스플레노펜틴 및 티모펜틴의 배합물 및 약제에서 이의 용도
ITMI20081652A1 (it) * 2008-09-16 2010-03-17 Antica Ritrovati Medicinal I S A R M Srl Soc Composizioni transdermiche per immunoterapia specifica iposensibilizzante
RU2698707C1 (ru) * 2019-04-29 2019-08-29 Федеральное государственное бюджетное научное учреждение "Федеральный Алтайский научный центр агробиотехнологий" (ФГБНУ ФАНЦА) Способ производства биогенных препаратов

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3146598A1 (de) * 1981-11-25 1983-07-07 Hoechst Ag, 6230 Frankfurt "neue peptide und verfahren zu ihrer herstellung"
DD271267A1 (de) * 1988-03-31 1989-08-30 Akad Wissenschaften Ddr Verfahren zur herstellung eines mittels zur normalisierung des immunsystems
HU199878B (en) * 1987-06-19 1990-03-28 Berlin Chemie Veb Process for producing acylated splenopentynes and pharmaceutical compositions comprising such compounds as active ingredient
DD263994A1 (de) * 1987-07-09 1989-01-18 Univ Halle Wittenberg Verfahren zur herstellung von oligodesoxyribonucleotiden zur splenopentinexpression
NZ229004A (en) * 1988-05-19 1993-09-27 Immunobiology Res Inst Inc Tetrapeptides having t cell helper acitivity
DD273980B5 (de) * 1988-07-12 1994-04-14 Berlin Chemie Ag Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung
DD296084A5 (de) * 1989-07-27 1991-11-21 Adw Verfahren zur herstellung von humanen spleninderivaten

Also Published As

Publication number Publication date
JPH0692315B2 (ja) 1994-11-16
ATE88903T1 (de) 1993-05-15
JPH04211611A (ja) 1992-08-03
EP0445581B1 (de) 1993-05-05
DD292382B5 (de) 1994-03-24
EP0445581A1 (de) 1991-09-11
DE59100098D1 (de) 1993-06-09
DD292382A5 (de) 1991-08-01
CA2037531A1 (en) 1991-09-07

Similar Documents

Publication Publication Date Title
DE3772521D1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
GB2219585B (en) Pharmaceutical composition
GB8927546D0 (en) Process for the production of biologically active tgf-beta
DE3768546D1 (de) Mittel zur verabreichung von hyaluronsaeure an saeuger.
DE69109284T2 (de) Verwendung von fluorierten löslichen tensiden zur herstellung von aerosolarzneimitteln mit dosierter abgabe.
NO890226L (no) Organopolysiloxanmasser som kan fornettes til elastomererved avspaltning av alkoholer.
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
EP0435682A3 (en) The use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
DK0458588T3 (da) Behandling af okulær hypertension med en synergistisk kombination til okulær administration
HUT49808A (en) Process for producing retarde pharmaceutical compositions containing aselastine
ATA145488A (de) Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
ES2055469T3 (es) Preparado inmunoestimulante, quimicamente estable y de aplicacion parenteral; procedimiento para su produccion y su aplicacion.
YU108691A (sh) Nove 3,3'-ditiobis (propionske kiseline) i njihovi estri
DE69015910D1 (de) Pharmazeutische Verwendung von Fettsäuren.
ATE117313T1 (de) Stabile lösungen von rebeccamycinderivaten sowie deren herstellung.
DE69331008D1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
ATE93745T1 (de) Konzentrierte pumpbare polyethercarboxylate.
CA2065889A1 (en) Increasing the choroidal blood flow
GB1291009A (es)
DK43891D0 (da) Pentapeptid og fremgangsmaade til fremstilling deraf
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
AU7945787A (en) Use of anipamil
HUT44802A (en) Process for producing pseudo-oligosaccharides and pharmaceutical compositions containing them
TH5681EX (th) รางส่งของ
TH6599EX (th) เก้าอี้

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 445581

Country of ref document: ES